Home / Publications / Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management

Publication - 2026Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management

Publication

Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management

Accepted for publication on May 18, 2026

Abstract

Despite growing evidence supporting the efficacy of azathioprine, methotrexate, and cyclosporine in halting vitiligo progression and promoting repigmentation, these agents remain underutilized in routine clinical practice.

Current treatment paradigms overwhelmingly favor corticosteroids as the first-line systemic intervention, especially in cases of rapidly progressive or generalized disease. However, this corticosteroid-centric approach does not adequately address the chronic, relapsing nature of vitiligo and does not offer a sustainable long-term strategy for disease control.

Vitiligo affects approximately 0.76–1.11% of the US population, with up to 40% of cases potentially remaining undiagnosed. The condition imposes a substantial psychosocial burden comparable to other chronic inflammatory diseases, with patients experiencing depression, anxiety, stigmatization, and significant quality-of-life impairment.

Patients often cycle through topical agents and repeated corticosteroid mini-pulses, achieving only temporary stabilization at the cost of accumulating adverse effects. Meanwhile, immunosuppressants with decades of safety data in autoimmune conditions such as lupus, psoriasis, and inflammatory bowel disease remain relegated to off-label or last-resort use in vitiligo.

In our view, this discrepancy between available evidence and clinical practice represents a substantial treatment gap.

We argue that azathioprine, methotrexate, and cyclosporine should no longer be relegated to off-label, last-resort use in vitiligo. Instead, they deserve structured, guideline-level consideration as systemic options for early disease stabilization and maintenance, particularly in patients for whom repeated corticosteroid pulses are unsafe, ineffective, or inaccessible.

In this Opinion, we outline the rationale for this shift and propose a pragmatic path toward integrating these agents into routine care.

Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management    Making the Case for Azathioprine, Methotrexate, and Cyclosporine in Active Vitiligo Management   

Yan Valle, Julia Sigova, Maria Borodina, Lyailya N. Kayumova, Liliya I. Almakaeva, Vladimir B. Pinegin, Konstantin Lomonosov



All Publications

FAQOther Questions

  • Can chemicals cause vitiligo?

    Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...

  • I have vitiligo: will my children have vitiligo, too?

    If you have vitiligo, it’s natural to worry about your children. While there is a genetic component, vitiligo is not a straightforward hereditary disease like eye color or heigh...

  • Can Ginkgo Biloba help with vitiligo?

    Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...